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Cirrhotic patients (CPs) are susceptible to spontaneous bacterial peritonitis (SBP). Aim of this study was
to examine if this susceptibility was related to peritoneal macrophages’ (PMs) altered host defence.
Absorbance of phagocytosed particles by PMs from CPs was lower than that of control (31.88% vs.
77.2%). Particle opsonisation increased the absorbance to 41% in CPs’ PMs, and this value remains lower
than the control; 77.2%. Respiratory burst (RB) was expressed as ﬂuorescence index values, and these
were higher in PMs from CPs than in controls (82 vs. 41, 73 vs. 26 and 71 vs. 26). IFN-gmade no further
increase of RB values in PMs from CPs. CD14 expression was also higher in CPs’ PMs. IFN-g signiﬁcantly
downregulated CD14 expression in both CPs’ PMs and control. Reduced phagocytosis by predominantly
CD14-positive PMs from CPs could be related to intense RB. Findings suggest altered host defence that
could contribute to susceptibility to SBP.
& 2011 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Spontaneous bacterial peritonitis (SBP) is a commonly occur-
ring infection among the patients with cirrhosis, and it is
associated with high morbidity and mortality. The pathogenesis
of SBP is not fully understood, but it is probably multi-factorial.
Bacterial translocation from the bowel lumen into the peritoneal
cavity has been demonstrated in portal hypertension models [1].
Defects in circulating polymorphonuclear and mononuclear pha-
gocytes have been reported [2,3].
Humeral factors such as the opsonising properties of serum
and ascitic ﬂuid, were also found to be deﬁcient [4,5], and the
phagocytic function of the hepatic reticuloendothelial system was
found to be decreased in approximately 50% of cirrhotic patients
[6,7]. Peritoneal macrophages (PMs) are predominantly resident
or tissue-type phagocytes and are presumed to constitute the
host’s ﬁrst line of defence in the peritoneal cavity.
Unlike circulating neutrophils, macrophages can phagocytose
avidly without prior opsonisation of ingestible particles [8]. Further-
more, macrophages undergo respiratory bursts (RBs), which are
necessary for microbial killing and are more or less similar to those
observed in neutrophils [9,10]. These two functions, phagocytosis
and RB, represent the fundamental characteristics of host defence inx: þ44 2073463167.
Ahmed).
Y-NC-ND license. PMs. In the murine system, these functions have been shown to be
inﬂuenced by certain cytokines, including granulocyte macrophage
colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-g)
[11,12].
Since an alteration in host defence mechanism could contri-
bute to the susceptibility to SBP, the aim of this study was (a) to
examine phagocytosis and RB in PM and (b) to examine if
applying potentially useful interventions might help in correcting
a detectable defect.2. Theory/calculation
Host defence is studied in a number of ways, and the choice
made to examine those two basic characteristics above (Section 1) is
justiﬁed. First both functions are quantitatively measured using
simple and reproducible techniques with a relatively small
number of cells. The cells used in this study were recovered from
patients with cirrhotic ascites, which is not particularly cell-rich.
The results were compared with those of peritoneal cells obtained
from a group of otherwise healthy women who were undergoing
gynaecological laparoscopic sterilisation. Second, the information
that is obtained from this research can be extended into further
examining detail components of the respective host defence
function. For instance, an impaired phagocytosis may indicate
further endocytic receptor studies, which mediate phagocytosis.
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that generates reactive oxygen intermediates.
If particle opsonisation corrected a detectable phagocytic
defect, the enhancement of the opsonic activity of ascitic ﬂuid
could be of practical beneﬁt. The same could apply to the
potential use of GM-CSF if it had been shown that this agent
would correct a phagocytic defect. Intense RB that is produced by
CD14-positive PMs might be harmful, and interventions that
optimise RB production may be developed.3. Materials
Nycoprep (Nycomed UK Ltd., Birmingham, England), Nunclon
(InterMed, Roskilde, Denmark). RPMI 1640, DMEM, Hank’s
Balanced Salt Solution and Foetal calf serum (FCS) were all from
Life Technologies Ltd., Paisley, UK. HEPES Buffered Saline (HBS),
EDTA, NaOH solution, Trypan blue, Candida albicans, Fluorescein
isothiocyanate (FITC), DMF, Zymosan and Lipopolysaccharide
(LPS) (Escherichia coli serotype 026 B6) were all from Sigma
Chemicals, Poole, UK. Anti-human CD14 monoclonal antibody
Leu-M3 FITC (Becton Dickinson Immunocytometry Systems,
San Jose, CA, USA), Dihydrorhodamine solution (DHR) (Cambridge
Biosciences, Cambridge, UK), Phorbol 12-myristate 13-acetate
(PMA) (Fisons Scientiﬁc Equipment, Loughborough, UK), Granu-
locyte macrophage colony-stimulating factor (GM-CSF), a gift
from Schering-Plough (UK) Ltd., Welwyn Garden City, Herts, UK,
Interferon-gamma (IFN-g), a gift from Boehringer Ingelheim (UK)
Ltd., Bracknell, UK.4. Patients and methods
4.1. Study population
The patient group comprised thirty patients with ascites, with
a mean age (7SD) of 51.477.7 years. Seventeen of these patients
were male. All patients had biopsy-proven cirrhosis and were
clinically graded as Child-Pugh class C. There was no clinical
evidence of SBP in any of these patients at the time of paracent-
esis. A neutrophil cell count of 4200 cell/mL in the ascitic ﬂuid or
in the control ﬂuid excluded the specimen from analysis. Ascitic
ﬂuid was aspirated during therapeutic paracentesis using a strict
aseptic technique and collected in 2-litre sterile containers. These
ﬂuid samples were placed on ice and transferred immediately to
the lab. Phagocytosis was measured in PMs from fourteen
patients, and RB was studied in PMs from seven patients. In these
seven patients, CD14 phenotype expression was also measured.
The control group comprised twelve female patients, with a
mean age of 3174.5 years, who attended the gynaecology unit as
scheduled day cases for laparoscopic fallopian tube ligation. None
of these controls had evidence of liver disease or a major system
disorder. Peritoneal ﬂuid specimens in these controls were
collected by the operating surgeon under direct vision from the
pouch of Douglas, as described elsewhere [13]. Phagocytosis was
measured in all the controls, and RB and CD14 expression were
measured in seven of the control samples. The control samples
were collected in sterile universal containers, placed on ice and
sent immediately to the laboratory. Neither the patients nor the
controls had been on any immune-modulating therapy within
three months of the procedure.
Informed written consent was obtained from all patients and
controls. Approval for this study was obtained from the King’s
College Hospital Research Ethics Committee, according to the
Declaration of Helsinki [14].4.2. Peritoneal macrophage (PMs) preparation
The samples were centrifuged twice at 600 g for ten minutes.
The cell pellets were re-suspended and layered over a density
gradient (Nycoprep, Nycomed UK Ltd., Birmingham, England) and
centrifuged at 600g for thirty minutes to obtain a monolayer [15].
The monolayer, which normally consists of monocytes, was
carefully aspirated and was washed twice in RPMI 1640. The
ﬁnal cell pellet was re-suspended in RPMI 1640 containing
penicillin 100 u/mL, streptomycin 100 mg/mL and 10% foetal calf
serum (FCS) (Life Technologies Ltd., Paisley, UK). A cell count was
then performed using a haemocytometer, and the cell morphol-
ogy was examined on cytocentrifuge preparations stained with
May Grunwald Giemsa. The purity of PMs was further determined
using non-speciﬁc esterase staining [16], and the cell viability was
determined by trypan blue dye exclusion. At this stage the cell
suspension was then kept at 0 1C until assayed.
4.3. Yeast preparation
C. albicans (Sigma Chemicals, Poole, UK) was heat killed by
placing it in a hot bath at 60 1C for one hour. The yeast particles
were then re-suspended and counted before labelling them with
ﬂuorescein isothiocyanate (FITC) (Sigma Chemicals, Poole, UK)
according to the method of Ragsdale and Grasso, with some
modiﬁcation [17]. Labelled yeast cells were re-suspended at
5107 cells/mL in 20% DMEM-FCS (Life Technologies, Paisley,
UK) stored in a light-protected environment at 4 1C. This stock
was used within ten weeks of preparation. Yeast particles opso-
nisation was performed with pooled human serum (PHS) col-
lected from healthy laboratory staff personnel and stored at
70 1C [18]. The opsonisation step was done one hour before
the phagocytosis assay.
4.4. Phagocytosis assay
PMs, which were prepared (1.3.3), were seeded at 0.5–1106
cells/well in 24-well tissue culture plates (Nunclon, InterMed,
Roskilde, Denmark) in RPMI/FCS at 37 1C and 5% CO2 air for two
hours to allow for cell adherence. Non-adherent cells were
thereafter gently washed out twice with warm HBSS (Life Tech-
nologies, Paisley, UK). The labelled yeast particles were added to
wells at a macrophage-to-particles ratio of 1:40 and phagocytosis
was allowed to proceed for thirty minutes. In experiments in
which GM-CSF was used, the cells were incubated with this
cytokine at concentrations of 50, 100 or 500 IU/mL for thirty-six
hours, and then phagocytosis was measured [19]. All samples
were assayed in duplicates.
At the end of this period, the plates were placed on ice and
washed twice with ice-cold HBSS, as described previously [17].
Each wash involved gentle pipetting up and down ten times after
which the supernatant was discarded. The plates were examined
using an inverted microscope between washings to determine the
number of internalised particles and to ensure that non-inter-
nalised particles, and not cells, were actually washed away. To
ensure that there were no free or non-internalised particles left
behind, the wells were rinsed once more with the same buffer in
some experiments, and the ﬂuorescence of the supernatant was
measured using a spectroﬂuorometer (RF-540 Shimadzu Corp,
Kyoto, Japan) at an excitation wavelength of 482 nm and an
emission wavelength of 520 nm [17].
Finally cells were lysed using 0.1 N NaOH, and the ﬂuorescence
of the liberated intracellular particles in the supernatant was
measured using spectroﬂuorometer (1.3.4). Values expressed as
arbitrary absorbance units’ percentages were calculated using the
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%A¼ ðF12F2Þ=ðF3Þ  100,
where %A is percent absorbance unit, F1 is the ﬂuorescence in the
wells containing both cells and particles, F2 is the ﬂuorescence in
the wells containing cells only (auto-ﬂuorescence) and F3 is the
ﬂuorescence in the wells containing labelled yeast particles only
(total ﬂuorescence).
4.5. CD14 phenotype
PMs (2104) in HEPES-buffered saline (containing 1.25 mM
CaCl2 and 1.25 mM MgCl2) and 2 mM EDTA (Sigma Chemicals,
Poole, UK) were incubated with 20 mL of the anti-human CD14
monoclonal antibody Leu-M3 FITC (Becton Dickinson Immunocy-
tometry Systems, San Jose, CA, USA) for twenty minutes on ice
[20]. The cells were then washed twice and re-suspended in
200 mL of the same solution and vortexed to disrupt any clumps of
cells. In experiments in which IFN-g was used, non-adherent cells
were ﬁrst incubated with this cytokine for forty-eight hours
at a concentration of 500 IU/mL. All samples were analysed in a
ﬂow cytometer (Becton Dickinson, Immunocytometry Systems,
San Jose, CA, USA) and the PMs were identiﬁed using a monocyte
gate. This gate was based on forward angle light scatter and log
901 light scatter parameters. Cell surface markers used other than
CD14 were CD5 and CD15. A signiﬁcant decrease in forward light
scatter was noted, with a smaller change in 901 light scatter,
which required a change in the gates. Monocytes were identiﬁed
utilising the FITC-conjugated anti-CD14.
4.6. Respiratory burst measurement
Respiratory burst measurement was performed according to
the method of Banati et al. [21], with some modiﬁcation. Brieﬂy,
aliquots of 2102 PMs in 200 mL HBS/EDTA were placed in
sterile capped ﬂow cytometer tubes and stained for ﬁve minutes
at 37 1C with 1.0 mL of 40 mM dihydrorhodamine solution (DHR)
(Cambridge Biosciences, Cambridge, UK). The DHR loaded-cells
were further incubated for thirty minutes at 37 1C with either
5 mL of 15 mM of phorbol 12-myristate 13-acetate (PMA) (Fisons
Scientiﬁc Equipment, Loughborough, England) in DMF, 10 mL of
12.5 mg/mL zymosan (Sigma Chemicals, Poole, UK) solution in
HBS or with 10 mL/mL lipopolysaccharide (LPS) (E. coli serotype
026 B6) (Sigma Chemicals, Poole, UK). In experiments in which
two stimuli were used the PMs were ﬁrst incubated with LPS for
one hour and then the second stimulant (PMA or zymosan) was
added for a further thirty minutes of incubation.
In experiments in which interferon-gamma (IFN-g) was used,
non-adherent cells were incubated for forty-eight hours with this
cytokine at varying concentrations (10–1000 IU/mL) before the RB
assay. RB was measured using a ﬂuorescence cell sorter (FACS)
with an argon ion laser at an excitation wavelength of 488 nm. ATable 1
Data related to patients and control groups and PM isolation.
Patients
Number 22
Male:female 11:11
Age (mean795% CL) 51.477.7 years
Aetiology of cirrhosis Alcoholic¼13
Primary sclerosing cholan
Viral hepatitis¼4
Cryptogenic¼1
Total number of cells isolated per mL 2.2470.87104 cells/mL
% of macrophages in cell mixture 85.272.4
Viability 9271.3%total of 2000 CD14-positive monocytes were analysed at a time.
DHR is oxidised intracellularly to rhodamine 123 in the presence
of hydrogen peroxide (H2O2) and peroxidase. A 525-nm band-
pass ﬁlter was used for the green ﬂuorescence from rhodamine
123, which represented the magnitude of RB activity. The data
were reported as a mean channel number (MCN) (256 channels, a
three-decade log scale in arbitrary log units). The ﬂuorescence
index was calculated by subtracting the MCN of the unstimulated
cells from the MCN of the stimulated cells (PMA, zymosan
and LPS).5. Statistical analysis
For data description, the mean and a 95% conﬁdence limit
were used. The Student’s t-test for paired samples and the
Wilcoxon’s test were used for analysing the results within each
group, and the Mann–Whitney U test was used for comparing the
results between the groups.6. Results
6.1. Peritoneal macrophages (PMs) characteristics
Table 1 shows the details of the patients and control groups
together with the PMs characteristics. 0.5–1.5 L of the ascitic ﬂuid
samples was used, which yielded an average total cell number of
2.2470.87104 cells/mL (Table 1). The ﬂuid samples from the
control group were smaller, between 7 and 20 mL, and yielded
a higher average cell number of 16.8713.2104 cells/mL
(Table 1). The percentages of PMs in the cell mixtures were
85.2% and 91% (p40.05) and the percentages of viable cells were
92% and 94% (p¼NS) for patients and controls, respectively.
When the plates were examined using an inverted microscope
following overnight incubation, we observed morphological
changes that became more prominent in the plates to which
GM-CSF had been added.
6.2. Yeast phagocytosis
The absorbance readings from internalised particles were
expressed as percentages of arbitrary units (AU) (Section 4.4),
and a standard mean value 795% CL was obtained for each
group. Fig. 1 shows the number of cases in which the absorbance
readings fall within the corresponding absorbance range on the
horizontal axis, where blue curve line represents patients’ PMs
readings and green curve line represents control PMs’. The mean
absorbance reading of the patient PMs (n¼14) was signiﬁcantly
lower than that of the control PMs (n¼12) (31.8878.0% vs.
77.275.64%, po0.01). The absorbance in the patients’ PMs
increased following particle opsonisation (brown-red curve line,Controls p-Value
12
0:12
3172.7 years
Laparoscopic sterilisation¼10
gitis (PSC)¼4 Diagnostic laparoscopy¼2
16.8713.2104 cells/mL p¼0.001
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94.171.86% p40.05
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Fig. 1. Phagocytosis measurement in patient and control PMs.
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sation, po0.05), although the absorbance remained signiﬁcantly
lower than that for unopsonised control PMs (41.24% vs. 77.2%,
po0.05).
Absorbance readings of supernatant ﬂuid aspirated from the
ﬁnal plate washings, and representing non-internalised particles,
were negligible (0.2–0.5%). A parallel qualitative observation was
made when phagocytosis was assessed using direct microscopy
examination and manually counting the ingested particles (data
not shown). Pre-incubation of the patient PMs (n¼10) with
GM-CSF had insigniﬁcant impact on phagocytosis (3079.4% before
compared to 3672.8.9% after, p¼0.998).
6.3. CD14 phenotype
CD14 expression was signiﬁcantly higher in the patient PMs
than in the control PMs (180 vs. 118 MCN, po0.05) (Fig. 2). AfterIFN-g treatment, the expression of CD14 was signiﬁcantly down-
regulated in the two groups (from 180 to 80 MCN in the patient
PMs (po0.05), and from 118 to 20 MCN in the control PMs
(po0.05) (Fig. 2). The downregulation was greater in the control
PMs than in the patients PMs (83% and 50%, respectively;
po0.05).
6.4. Respiratory burst
The RB ﬂuorescence index values for patient PMs were
signiﬁcantly higher than those for the control PMs following
stimulation with a single agent (PMA, 82 vs. 41; LPS, 73 vs., 44;
zymosan, 71 vs. 26; po0.005) (Fig. 3).When two agents, PMA and
LPS, were used in combination for stimulation, the RB index
values further increased by 40% (from 82 to 115) in the patient
PMs and by 130% in the control PMs (from 41 to 95) (po0.005)
(Fig. 3). When the cells were treated with IFN-g and then
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Fig. 3. Measurement of Respiratory Burst (RB) in patients’ PM (dark bars) and controls (light bars) PM.
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increase of 6% (from 82 to 87) in the patient PMs and 22% (from
41 to 50, po0.05) (Fig. 4) in the control PMs.7. Discussion
In this study, we extended the work of other investigators on
peritoneal macrophages [22–24]. First, unlike the studies on
macrophage function that used cells isolated from healthy donors,
this study is one of a few in which the cells were isolated from ill
patients. Second, although studies in healthy PMs, and in parti-
cular, those from the murine system have provided most of the
available knowledge in this area, studying these cells in relation
to cirrhotic ascites and SBP is clearly very relevant.
The control PMs used by other investigators were isolated from
dialysate ﬂuid, which was removed from renal patients undergoingcontinuous ambulatory peritoneal dialysis (CAPD). Because exogen-
ous solutions used in CAPD perturb the peritoneal environment, the
behaviour of the PMs isolated from dialysate ﬂuid could be inﬂuenced
[25]. The control PMs used in this study were similar to the patient
PMs because both cell populations matured in an in vivo human
environment and without the effect of exogenous factors. Not
surprisingly, the total number of cells isolated from cirrhotic ascites
exceeded that isolated from the controls, because the volume of
ascites irrigates a greater surface area of the peritoneum.
Previous studies have reported reduced phagocytosis in per-
ipheral blood monocytes and in the Kupffer cells of cirrhotic
patients (CP) [3,6,7]. This reduced phagocytosis was explained by
intrinsic cell defects and by the presence of phagocytosis inhibi-
tory factors. These ﬁndings may not necessarily be extrapolated
to the PMs because the peritoneum environment in which the
PMs reside is different from the environments, the circulation and
the reticuloendothelial system, in which the peripheral blood
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ﬁnding in this study of reduced phagocytosis in PMs from
cirrhotic patients has not been previously reported. Unlike the
situation with neutrophils, particle opsonisation is not a pre-
requisite for phagocytosis by macrophages. Opsonisation is
known to further augment this function [26].
However, in the present study although phagocytosis
increased following particle opsonisation it was still much lower
than that recorded in the control PMs before opsonisation. This
result implies that the defect is probably on the PM cell surface.
Phagocytosis is a process mediated via surface receptors that
recognise the chemical structure of the particle to be internalised.
For example yeast and bacteria are covered in glycoconjugates
that are recognised by an endoreceptor macrophage mannose
receptor (MR), which mediates phagocytosis [27–29]. Although
yeast is not a common SBP-causing pathogen, its structure in
relation to the endocytic process may resemble that of the
bacteria that cause SBP.
GM-CSF is reported to enhance phagocytosis in normal macro-
phages [12]. This was not demonstrable in the present study; this
result is not surprising as GM-CSF primarily induces monocytes to
develop into a more mature and efﬁcient form of phagocytes [8].
In our study, the PMs were already mature. More recently,
interleukin-4 (IL-4) has been shown to have an upregulatory
effect on the expression of the endocytic receptor MR [30], and
currently, this issue is being investigated in our laboratory.
Reactive oxygen intermediates (ROI) are generated during RB,
and they would provide a clear indication of the ability of cells to
destroy invading organisms and would also reﬂect the cytotoxic
capability. There are, of course, other agents involved in macro-
phage effector function, including NO and myeloperoxidase.
However, RB in particular is a more robust microbicidal mediator,
and its measurement could be more reﬂective of this effector
function. The vigorous RB response recorded in patient PMs is of
interest. Previous studies have shown that the ability of human
PMs to undergo a RB is limited and may even decline if the cell
culture period is extended [24]. This ﬁnding prompted us to
prime cells with LPS ﬁrst and then add another stimulus, such as
PMA to increase the chances of producing the desired RB effect.
Furthermore, the period from the beginning of the incubation
until the time of the RB assay was kept relatively short to
minimise any loss in RB produced. The result was that the RB
was even greater in patient PMs. This intense RB was perhaps
partly due to the experimental factors above and partly due to a
possibility of pre-existing in vivo cell activation. We observed that
the cell morphology changed during the short incubation period,
even in the wells to which no cytokine had been added. These
observed changes may be similar to the morphological changes in
activated macrophages that have been reported by other
researchers [31,32]. In addition, we observed a small increase in
the RB following the treatment of cells with IFN-g, which is also
consistent with an already activated state. Although intense RB
activity is a desirable effector function that is essential for
microbial killing, it is by no means without a caveat. The
expression of relevant endocytic receptors involved in phagocy-
tosis has been shown to be downregulated by intense RB,
resulting in reduced phagocytosis [33]. CD14-positive macro-
phages, as opposed to their CD14-negative counterparts, are more
involved in RB. Furthermore, the magnitude of CD14 expression in
the mature macrophages is greater than that in the less mature
macrophages [34]. It is of interest that CD14 expression was
found to be more abundant in the PMs from cirrhotic patients
compared to those of controls, and this difference in the magni-
tude of CD14 expression could contribute to the RB result.
Consistent with other studies, our study has further conﬁrmed
the downregulatory effect of IFN-g on CD14 expression [22,23].CD14 binds LPS, and as a result, the release of pro-inﬂammatory
cytokines, including TNF-a, is mediated. Because TNF-a is
involved in the pathogenesis of shock syndrome [23], the down-
regulatory effect of IFN-g on CD14 expression may potentially
have a protective effect on the host in complex situations such as
shock syndrome.8. Conclusion
We have shown for the ﬁrst time that the host defence of PMs
from cirrhotic patients with ascites is altered. The predominance
of activated CD14 expressing cells has generated a vigorous RB,
which in turn had a downregulatory effect on endocytic receptors.
This mechanism could account for the reduced phagocytosis
reported. Such an alteration in host defence may in part play a
role in the increased susceptibility of these patients to SBP.Acknowledgement
We are grateful to Anne Etches from Haematology Department
at King’s College Hospital, London, UK, for her help with macrophage
characterisation studies. We are also grateful to Schering-Plough
(UK) Ltd., Welwyn Garden City, Herts, UK, for providing the GM-CSF
and to Boehringer Ingelheim (UK) Ltd., Bracknell, UK, for providing
the interferon-gamma.References
[1] Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute
and chronic portal hypertension. Hepatology 1993;17(6):1081–5.
[2] Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intra-
cellular killing and metabolic activity of alcoholic cirrhosis and hepatitis.
Hepatology 1986;6:252–62.
[3] Hassner A, Kletter Y, Schlag D, Yedvab M, Aronson M, Shibolet S. Impaired
monocyte function in liver cirrhosis. British Medical Journal 1981;282:
1262–3.
[4] Wyke RJ, Rajkovic IA, Williams R. Impaired opsonization by serum from
patients with chronic liver disease. Clinical and Experimental Immunology
1983;51:91–8.
[5] Simberkoff MS, Moldover NH, Weiss G. Bactericidal and opsonic activity of
cirrhotic ascites and non-ascitic ﬂuid. Journal of Laboratory and Clinical
Medicine 1978;91:831–9.
[6] Rimola A, Soto R, Bory F, Arroyo B, Piera C, Rodes J. Reticuloendothelial
system phagocytic activity in cirrhosis and its relation to bacterial infections
and prognosis. Hepatology 1984;4(1):53–8.
[7] Bolognessi M, Markel C, Bianco S, Angeli P, Sacerdotti D, Amadio P, et al.
Clinical signiﬁcance of the evaluation of hepatic reticuloendothelial removal
capacity in patients with cirrhosis. Hepatology 1994;19(3):628–34.
[8] Marodi L, Korchak HM, Johnson Jr RB. Mechanisms of host defence against
Candida species. Phagocytosis by monocyte and monocyte-derived macro-
phage. Journal of Immunology 1991;146:2783–9.
[9] Babior BM, Kipnes RS, Curnutte JT. Biological defence mechanisms. The
production of leukocytes of superoxide, a potential bactericidal agent. Journal
of Clinical Investigation 1973;52:741.
[10] Fantone JC, Ward PA. Role of oxygen-derived free radicles and metabolites in
leukocyte-depedent inﬂammatory reactions. American Journal of Pathology
1982;107:397.
[11] Murray HW. Interferon-gamma, the activated macrophage and host defence
against microbial challenge. Annals of Internal Medicine 1988;108:595–608.
[12] Weisbart RH, Gasson JC, Golde DW. Colony stimulating factors and host
defence. Annals of Internal Medicine 1989;110:297–303.
[13] van Furth R, Raeburn JA, Van Zwet TL. Characteristics of human mononuclear
phagocytes. Blood 1979;54:485–98.
[14] Human Experimentation. Code of ethics of the World Medical Association,
Declaration of Helsinki. British Medical Journal 1964;ii:177.
[15] Boyum A. Isolation of human blood monocytes with Nycodenz. A new non-
ionic iodinated gradient medium. Scandinavian Journal of Immunology
1983;17:429–36.
[16] Yam LT, Li CY, Crosby HW. Cytochemical identiﬁcation of monocytes and
granulocytes. American Journal of Clinical Pathology 1971;55:283–90.
[17] Ragsdale RL, Grasso RJ. An improved spectroﬂuorometry assay for quantitat-
ing yeast phagocytosis in cultures of murine peritoneal macrophages. Journal
of Immunological Methods 1989;123:259–67.
A.M.M. Ahmed et al. / Results in Immunology 1 (2011) 53–59 59[18] Peterson PK, Gaziano E, Suh JA, Devalon M, Peterson L, Keane WF. Anti-
microbial activities of dialysate-elicited and resident human peritoneal
macrophages. Infection and Immunity 1985;49:212–8.
[19] Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function
against Candida albicans by the colony stimulating factors (CSF): IL3, GM-CSF
and M-CSF. Journal of Immunology 1989;143:671–7.
[20] Banati RB, Rothe G, Valet G, Kreutzberg W. Respiratory burst activity in brain
macrophages: a ﬂow cytometric study on cultured rat microglia. Neuro-
pathology and Applied Neurobiology 1991;17:223–30.
[21] Zeller JM, Rothberg L, Landay AL. Evaluation of human monocytes oxidative
metabolism utilizing a ﬂow cytometric assay. Clinical and Experimental
Immunology 1989;78:91–6.
[22] Nathan CF, Murray HW, Weibe ME, Rubin BY. Identiﬁcation of IFN-g as the
lymphokine that activates human macrophage oxidative metabolism and
antimicrobial activity. Journal of Experimental Medicine 1983;158:670–89.
[23] Payne JB, Nichols FC, Peluso JF. The effect of interferon-g and lipopolysac-
charide on CD14 expression in human monocytes. Journal of Interferon
Research 1992;12:307–10.
[24] Pruimboom WM, van Dijk APM, Tak CJAM, Zijlstra FJ, Bonta Il, Wilson JHP.
Inﬂammatory mediators and activity of human peritoneal macrophages.
Agents Actions 1993;38:C86–8.
[25] Peterson PK, Gaziano E, Suh JA, Devalon M, Peterson L, Keane WF. Anti-
microbial activities of dialysate-elicited and resident human peritoneal
macrophages. Infection and Immunity 1985;49:212–8.
[26] MacGowan AP, Peterson PK, Keane W, Quie PG. Human peritoneal macro-
phage phagocytic, killing and chemiluminescent responses to opsonized
Listeria monocytogenes. Infection and Immunity 1983;40:440–3.[27] Stahl PD, Rodman JS, Miller MJ, Schreiber PH. Evidence of receptor-mediated
binding of glycoproteins, glycoconjugates and lysosomal glycosidases by
alveolar macrophages. Proceedings of the National Academy of Sciences
1978:1399–402.
[28] Wilson ME, Pearson RD. Evidence that Leishmania donovani utilizes a
mannose receptor on human mononuclear phagocytes to establish intracel-
lular parasitism. Journal of Immunology 1986;136:4681–7.
[29] Speert DP, Wright SD, Silverstein SC, Mah B. Functional characterization of
macrophage receptors for in vitro phagocytosis of unopsonized Pseudomonas
aeruginosa. Journal of Clinical Investigation 1988;82:872–9.
[30] Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances
alternative murine macrophage mannose receptor activity: a marker of
immunologic macrophage activation. Journal of Experimental Medicine
1992;176:287–92.
[31] Hart PH, Jones JA, Finlay-Jones JJ. Peritoneal macrophages during peritonitis.
Phenotypic studies. Journal of Immunology 1992;88:484–91.
[32] Berton G, Gordon S. Superoxide release by peritoneal and bone marrow-
derived mouse macrophages. Modulation by adherence and cell activation.
Immunology 1983;49:693–704.
[33] Ezekowitz RAB, Austyn J, Stahl PD, Gordon S. Surface properties of Bacillus-
Calmette–Guerin-activated mouse macrophages. Reduced expression of
mannose-speciﬁc endocytosis, Fc receptors and antigen F4/80 accompanies
induction of Ia. Journal of Experimental Medicine 1981;154:60–76.
[34] Eischen A, Duclos B, Schmitt-Goguel M, Rouyer N, Bergerat JP, Hummel M,
et al. Human resident peritoneal macrophages: phenotype and biology.
British Journal of Haematology 1994;88:712–22.
